scholarly journals P6062Predicting outcome with normal-range high-sensitivity troponin i and heart-type fatty acid-binding protein in stable patients with suspected coronary artery disease

2017 ◽  
Vol 38 (suppl_1) ◽  
Author(s):  
J.S. Wolter ◽  
S. Kriechbaum ◽  
N. Osman ◽  
C. Troidl ◽  
U. Fischer-Rasokat ◽  
...  
2009 ◽  
Vol 160 (2) ◽  
pp. 165-172 ◽  
Author(s):  
E J Rhee ◽  
W Y Lee ◽  
C Y Park ◽  
K W Oh ◽  
B J Kim ◽  
...  

ObjectivesAdipocyte fatty acid-binding protein (A-FABP), also known as aP2 or FABP4, is abundantly expressed in adipocytes and plays a role in glucose homeostasis. We analyzed the relationship between the coronary artery disease and serum FABP4 levels in Korean adults.MethodsIn a total of 234 Korean adults, in whom coronary angiograms were performed, anthropometric measurements were done and fasting glucose and lipid profiles were measured. Serum FABP4 levels were measured using ELISA. The presence of metabolic syndrome was diagnosed according to American Heart Association/National Heart, Lung and Blood Institute (AHA/NHBL) criteria with body mass index (BMI) substituted for waist circumference.ResultsAmong the subjects, 31.6% had diabetes, 46.9% had metabolic syndrome, and mean log (FABP4) levels showed significantly higher levels in subjects with diabetes. Among the subjects, 42.4% had normal coronary vessel, 34.6% had 1-vessel disease, 13.7% had 2-vessel disease, and 9.4% had 3-vessel disease. Among the parameters, mean age, fasting glucose, and log (FABP4) levels increased significantly as the numbers of stenotic vessel increased from normal to 3-vessel disease, and for FABP4, these significances showed a consistent trend for difference after adjustment for age, gender, BMI, and fasting glucose (P=0.072). Mean log (FABP4) level showed lower values in subjects taking aspirin, and higher values in subjects taking statin and anti-hypertensive drugs.ConclusionsSerum FABP4 levels increased as the numbers of stenotic coronary artery increased, although these differences were attenuated after adjustment for age and fasting glucose levels. Various anti-atherogenic medications showed different effects on the serum FABP4 levels, which need further investigation.


2017 ◽  
Vol 43 (1) ◽  
pp. 30-39
Author(s):  
Cihan Coşkun ◽  
Alper Gümüş ◽  
Hümeyra Öztürk Emre ◽  
Birol Özkan ◽  
Selçuk Pala ◽  
...  

AbstractObjective:In this study, we investigated the correlation between coronary lesion complexity as characterized by syntax score (SS) with circulating adiponectin and adipocyte-fatty acid binding protein (A-FABP4) concentrations in the presence of stable coronary artery disease affecting three coronary vessels (three-vessel stable CAD).Methods:The study groups consisted of 41 control subjects (28 males and 13 females, non-CAD group) and 115 affected subjects (79 males and 36 females, three-vessel stable CAD group). We divided into tertiles the three-vessel stable CAD group according to SS and estimated circulating concentrations of adiponectin and A-FABP4.Results:We did not find any correlation between the coronary lesion complexity with either the adiponectin and/or A-FABP4. We found lower the A-FABP4 of the non-CAD group than those of the groups with three-vessel stable CAD (p<0.001). Adiponectin were lower in DM subjects (p<0.05 for each group); though A-FABP4 were found to be higher (p<0.05 for each group) according to non-DM subjects in intra-group comparisons.Conclusion:Adiponectin is not a suitable parameter for demonstrating the existence of CAD or predicting coronary lesion complexity. A-FABP4 is more useful for the proof of the presence of CAD but A-FABP4 are not correlated with the severity of CAD.


2012 ◽  
Vol 50 (2) ◽  
Author(s):  
Eftihia Sbarouni ◽  
Panagiota Georgiadou ◽  
Maria Koutelou ◽  
Mihas Constantinos ◽  
Antigoni Chaidaroglou ◽  
...  

AbstractHeart-type fatty acid-binding protein (H-FABP) is a marker of myocardial necrosis, but whether it increases during myocardial ischemia is not known. This study investigated whether serum levels of H-FABP change during adenosine stress testing and nuclear imaging in patients with stable coronary artery disease.Thirty stable patients with established coronary artery disease on their medications were studied. Sampling was performed before the stress test, at the end of adenosine infusion, as well as 1, 2 and 3 h after the completion of the infusion.No difference in H-FABP serum levels were found at the five pre-specified time points in the overall group (p=0.99); furthermore, there was no significant difference regardless of the test result – positive (p=1) or negative (p=0.98).It is concluded that H-FABP does not change significantly during pharmacologic stress testing in patients with known coronary artery disease and there is no difference whether there is inducible ischemia or not.


Sign in / Sign up

Export Citation Format

Share Document